Not recommended in patients w/ dementia-related psychosis &/or behavioural disturbances; Parkinson's disease. Caution in patients w/ prostatic hypertrophy, paralytic ileus & related conditions; low leukocyte &/or neutrophil counts; history of seizures or patients subject to factors which may lower the seizure threshold. Neuroleptic malignant syndrome. Observe for signs & symptoms of hyperglycaemia. Monitor patients w/ DM or risk factors for DM for worsening of glucose control. Lipid alterations. Transient, asymptomatic elevations of hepatic aminotransferases. Discontinue if Drug Reactions w/ Eosinophilia & Systemic Symptoms (DRESS) is suspected. QTc prolongations. Venous thromboembolism. Combination w/ other centrally acting medicines & alcohol. Risk of tardive dyskinesia increases w/ long-term olanzapine exposure. Postural hypotension in elderly. Sudden cardiac death. May affect ability to drive or operate machinery. Pregnancy & lactation. Not indicated for childn & adolescents. Zyprexa tab
Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Zyprexa Zydis
Phenylketonurics. Contains mannitol, Na methyl parahydroxybenzoate & Na propyl parahydroxybenzoate. Zyprexa inj
Patients w/ agitation & disturbed behaviours related to conditions other than schizophrenia or manic episode; unstable medical conditions eg, acute MI, unstable angina pectoris, severe hypotension &/or bradycardia, sick sinus syndrome, or following heart surgery. Concomitant use of benzodiazepines & other medicinal products having haemodynamic properties similar to IM olanzapine. Observe patient for hypotension particularly for the 1st 4 hr following inj.